Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2017 · 10-Q
Revenue—
Net Income-$6.67M-$6.67MN/M vs Q3 2016 EPS Diluted-$0.03-$0.03N/M vs Q3 2016 Operating Income-$1,035,628N/M Operating Cash Flowderived-$828,857N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end